Business context and reporting period
The supplied filing is ChromaDex Corporation’s Form 10-K, not a filing under the name Niagen Bioscience, Inc. It covers the fiscal year ended January 3, 2015 (53 weeks), compared with the year ended December 28, 2013 (52 weeks). ChromaDex develops and sells proprietary ingredients, phytochemical reference standards, analytical and contract services, and scientific and regulatory consulting. NIAGEN was a recently launched ingredient and a principal driver of ingredient growth.
Financial performance and liquidity
| Metric | Year ended Jan. 3, 2015 | Prior year |
|---|---|---|
| Net sales | $15.31 million | $10.16 million |
| Gross profit | $5.33 million; 34.8% margin | $3.13 million; 30.8% margin |
| Operating loss | $5.23 million | $4.39 million |
| Net loss | $5.39 million; $0.05 per share | $4.42 million; $0.04 per share |
| Cash used in operating activities | $2.58 million | $3.91 million |
| Cash at year-end | $3.96 million | $2.26 million |
Current assets were $9.90 million and current liabilities $4.98 million at year-end. The company reported $2.5 million drawn on its Hercules term loan, plus $571,000 in capital lease obligations. The loan is secured by substantially all assets other than intellectual property, carries a stated minimum rate of 9.35%, and includes a further $2.5 million available to draw by July 31, 2015. Management expected available cash, operating cash generation, and that optional draw to fund its projected operating plan through at least March 20, 2016; this is not a guarantee of adequate funding.
Material changes versus the prior comparable period
- Sales increased 51%. Ingredient sales rose 182% to $6.86 million, chiefly on NIAGEN; core standards and contract services rose 13% to $7.49 million. Consulting sales fell 16% to $969,000.
- Gross profit grew 70% and margin improved by about 4 percentage points, reflecting higher sales and utilization in core services and ingredient growth.
- General and administrative expense rose 64% to $8.37 million, including higher share-based compensation ($2.92 million versus $1.29 million), patent-related costs ($815,000 versus $294,000), and R&D ($514,000 versus $134,000). Sales and marketing expense declined 9%.
- Net loss widened 22%, despite the higher gross profit, as operating expenses and interest expense increased. Operating cash use decreased, but year-end receivables more than doubled to $1.91 million and inventory rose to $3.73 million.
- The company sold its remaining NeutriSci preferred shares in 2014 and reported no investment in NeutriSci at year-end; investing cash inflows included proceeds related to that investment.
Outlook, risks, contingencies, and unusual items
Management planned to continue increasing R&D on proprietary ingredients, subject to available resources, and expected operating expenses to remain under pressure as the business expanded. No quantified revenue or earnings guidance was provided. The company cautioned that it may need additional financing and had no commitment for such funding; inability to raise capital could delay or curtail development and expansion.
- Key risks include recurring losses and accumulated deficit of $39.52 million, reliance on NIAGEN and other products gaining market acceptance, regulatory and clinical uncertainty, competition, patent protection, customer demand, and dependence on third-party suppliers and manufacturing.
- Inventory includes slow-moving reference standards with an operating cycle longer than one year; management’s valuation depends on demand and obsolescence estimates.
- The 2014 results included a $125,000 settlement expense and elevated equity compensation, including restricted-stock awards. The company also issued a warrant to its lender and has substantial outstanding options and warrants, creating potential dilution.
- Minimum future operating lease payments were $1.50 million; minimum royalties and license-maintenance payments for the next five years totaled $1.55 million. Ordinary-course legal matters were disclosed, but management did not expect them to have a material adverse effect.
- Marcum LLP issued unqualified opinions on the financial statements and internal control over financial reporting. Management also concluded disclosure controls and internal controls were effective as of year-end.
Important facts for investors to verify
- Confirm the issuer and filing identity: the source is for ChromaDex Corporation, while the request names Niagen Bioscience, Inc.
- Check subsequent results against management’s stated funding runway and whether the optional $2.5 million loan tranche was drawn by its deadline.
- Track NIAGEN sales, customer concentration, margins, and collections; receivables and inventory increased substantially alongside ingredient growth.
- Review debt covenants, loan conversion and warrant terms, lease and royalty commitments, and potential dilution from equity awards and securities.
- Assess whether clinical evidence, regulatory clearances, patent rights, and manufacturing capacity support the company’s commercialization plans.